Company intelligence / Profile preview

Viral Vector Manufacturing Facility

Sydney, New South Wales, Australiavvmf.org ↗

Ownership: Private
Development stage: Other

Overview

Viral Vector Manufacturing Facility is Australia’s first commercial-scale facility dedicated to the design, development, and GMP manufacture of clinical and commercial grade viral vectors. It supports research through to Phase I/II clinical supply with capabilities in both lentiviral and adeno-associated viral vectors. The company partners with biotechs and pharma globally to enable cell and gene therapy development by providing high-quality viral vector solutions.

Modalities: Recombinant lentiviral vector (rLV)Recombinant adeno-associated viral vector (rAAV)
Industry: Contract Manufacturing Organization

Partnerships

Cytiva (bioprocessing technology partner)Biointelect (strategic planning partner)

Beyond the preview

Go deeper on Viral Vector Manufacturing Facility.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viral Vector Manufacturing Facility.

Explore the full profile